Bimagrumab
An antibody that blocks the activin type II receptor — the docking station myostatin uses to tell muscle to stay small. Originally a Novartis muscle drug, now owned by Eli Lilly and being tested with semaglutide for fat loss that spares (or even adds) muscle.
What people claim
Lose fat and keep — possibly gain — muscle at the same time, especially stacked with a GLP-1.
Human evidence
The best-studied of the three muscle-preservation antibodies. A 2021 randomised trial in adults with obesity and type 2 diabetes (JAMA Network Open) reported meaningful fat-mass loss with lean-mass gain — an almost unheard-of combination. The phase 2b BELIEVE trial then paired it with semaglutide, with reported results showing large total weight loss where the overwhelming majority came from fat. Still phase 2 territory: encouraging, repeatedly, but not yet the large phase 3 evidence that settles a question.
Animal evidence
Strong preclinical biology on ActRII blockade driving muscle growth — consistent with the broader myostatin-pathway story (naturally 'double-muscled' animals). The human trials are what matter here.
Risk flags
- Long-term effects unknown
- Unregulated / grey-market supply
- Purity & quality unknowable
- Banned in tested sport (WADA)
Regulatory status
US: Investigational. NOT FDA-approved. Novartis previously took it to phase 3 for a rare muscle disease (sIBM), where it failed its endpoint; the obesity programme under Eli Lilly is still in trials.
UK: Investigational; no MHRA authorisation.
Everyone's an expert
Who says what
Gym Bros Say
"The one where you lose 20% of your bodyweight and it's basically all fat. Lilly bought the company for a reason."
Reddit Says
The most-cited of the myostatin-pathway drugs, because the 2021 trial actually showed lean-mass GAIN during fat loss. Also regular threads pointing out that grey-market 'bimagrumab' can't plausibly be real.
Big Pharma Says
Eli Lilly paid up to ~$1.9bn for Versanis largely to get this molecule — the clearest possible signal that the industry believes muscle-sparing weight loss is the next battleground.
Science Actually Says
Grade B: multiple randomised human trials, including a striking body-composition result in 2021 and a large phase 2b with semaglutide. Caveats are real — a failed phase 3 in a different disease, muscle-spasm side effects reported, and long-term safety of chronic ActRII blockade unestablished.
PeptideStackers Says
The strongest current evidence that 'burn fat, keep muscle' can be drugged. Also a two-week-half-life monoclonal antibody that no bathtub lab on earth can synthesise — if a vendor claims to sell it, that tells you everything about the vendor.
Honesty section
What we still don't know
- ?Long-term safety of blocking ActRII, a receptor involved in more than just muscle.
- ?Whether added or preserved lean mass translates into strength and function.
- ?Durability — what body composition does after treatment stops.
- ?Full side-effect picture at scale (earlier trials noted muscle spasms and diarrhoea).
Real questions people ask
FAQ
- Is bimagrumab available?
- No. It's an investigational drug owned by Eli Lilly, in trials. There is no legitimate way to obtain it, and no approved product exists in any country.
- Is bimagrumab a peptide?
- No — it's a full monoclonal antibody, a large biologic made in living-cell bioreactors. That matters practically: it can't be made by peptide-synthesis vendors, so grey-market listings are almost certainly not the real molecule.
- Does bimagrumab build muscle?
- In the 2021 trial, participants gained lean mass while losing substantial fat — one of the most interesting body-composition results ever published. Whether that repeats at scale, lasts, and translates to strength is exactly what the current trials exist to answer.
Before you do anything
Questions to ask a qualified professional
- 01What can I do today, with actual evidence behind it, to protect muscle while losing weight?
- 02If muscle-sparing drugs get approved, which would suit my situation — and what monitoring would they need?
- 03How would anyone verify a grey-market 'antibody' is real, given the manufacturing involved?